We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

By LabMedica International staff writers
Posted on 25 Apr 2025

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. More...

Deubiquitinating (DUB) enzymes contain around 100 proteins that remove ubiquitin from a variety of substrates. Widely involved in the regulation of cellular processes including cell proliferation, autophagy, DNA damage repair, and immune response – DUBs have been implicated in a range of human diseases and consequently are attractive targets for potential therapeutic intervention via the development of suitable inhibitors and modulators. Now, a new range of DUB enzyme assay kits can accelerate routine DUB activity assays without compromising data quality.

AMS Biotechnology (Amsbio, Abingdon, England) has launched a new range of DUB enzyme assay kits supplied in a convenient and easy-to-use 96-well assay format. These ready-to-use kits require minimal setup and no need for substrate preparation. The new kits are based on ubiquitin derivatives conjugated with various fluorophores that enable sensitive and specific detection using a microplate reader at an excitation wavelength of 485 nm and an emission wavelength of 535 nm. The range includes kits tailored to individual DUB enzymes such as BAP1, USP7, and UCHL1, enabling researchers to precisely profile activity or screen inhibitors against disease-relevant targets.

Designed to quickly measure deubiquitinase activity or inhibitor screening in purified enzyme systems and cell-based models – these new assay kits come optimized for both kinetic and endpoint analysis. Supplied in an industry standard 96-well microplate format these DUB enzyme assay kits are high throughput screening compatible and ready-to-use by academic, biotech and pharma researchers. The areas of research that may benefit from these kits include cancer tumor suppression and cell cycle regulation; neurodegenerative diseases, such as Parkinson’s, via mitochondrial and protein clearance pathways and immune system function and inflammation, where DUBs regulate cytokine signaling and innate immunity.

Related Links:
Amsbio


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Blood Gas and Chemistry Analysis System
Edan i500
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.